Abstract
Background: The combination therapy of anti-platelet medication and PPI/H2RA was recommended but yet being controversial due to the safety issue. To evaluate the efficacy and safety of the combination therapy of ticagrelor and PPI/H2RA on patients with acute STEMI receiving PCI. Methods: A total of 170 patients were hospitalized for PCI due to acute STEMI. The patients were divided into 4 groups receiving pantoprazole+ ticagrelor, omeprazole+ ticagrelor, ranitidine+ ticagrelor and ticagrelor only, respectively. The the prognosis of the therapy was evaluated and compared to verify the efficacy and safety of the combination therapy. Findings: No significant differences were found in IRA perfusion indexes (TIMI, CTFC), incidence of stent thrombosis after PCI, platelets indicators (PLT, MPV, PDW), platelets activation (P-selectin and GPIIb/IIIa levels), TEG indicators (ADP%, MAADP), myocardial necrosis biomarker (CK-MB, cTnI) and BNP levels between the 4 groups of patients after 7 days of follow-up. Patients receiving PPI+tecagrelor had significantly better safety profile than those who were given ticagrelor only. Interpretation: Based on our findings, the combinational application of tecagrelor and PPI yielded a satisfying safety profile in patients with acute STEMI after PCI. Funding Statement: None. Declaration of Interests: The authors declare that they had no competing interests. Ethics Approval Statement: This work was approved by the Ethics Committee of The First Affiliated Hospital with Nanjing Medical University. Written informed consent was obtained from all patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call